BerGenBio

Remuneration Information • Nov 5, 2018

BerGenBio ASA: Share options to primary insiders

BerGenBio ASA: Share options to primary insiders

Bergen, Norway, 5 November 2018 - The board of directors in BerGenBio ASA (the "Company") (OSE:BGBIO) has granted options to primary insiders.

The annual general meeting in the Company at 14 May 2018 approved the share options program. Options granted under the option program is vested over a three-year period and each option, when exercised, will give the right to acquire one share in the Company.

A total of 277,000 share options were granted at an exercise price at NOK 28.50, of this the following was granted to primary insiders (total holdings of share options following this grant):

Richard Godfrey - CEO: 50,000 (1,117,484)

Rune Skeie - CFO: 20,000 (44,090)

James B. Lorens - CSO: 7,000 (717,707)

Anthony Brown - Director of research: 10,000 (186,499)

Endre Kjærland - Associate Director of IP and Contracts: 10,000 (95,225)

Julia Schoelermann - Associate Director of Business development: 20,000 (100,418)

Sonia Rodrigues – Director of Regulatory affairs: 10,000 (36,499)

Tone Bjaaland - Director of Clinical operations: 45,000 (45,000)

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.